Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice.

OnabotulinumtoxinA has been demonstrated to be effective as a preventive treatment in patients with chronic migraine (CM). Five years after the approval of onabotulinumtoxinA in Spain, the Headache Study Group of the Spanish Society of Neurology considered it worthwhile to gather a group of experts...

Descripción completa

Detalles Bibliográficos
Autores: Gago-Veiga AB, Santos-Lasaosa S, Cuadrado ML, Guerrero ÁL, Irimia P, Láinez JM, Leira R, Pascual J, Sanchez Del Río M, Viguera J, Pozo-Rosich P
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p2283
Acceso en línea:https://incliva.portalinvestigacion.com/publicaciones/2283
Access Level:acceso abierto
Palabra clave:Consensus
Chronic migraine
OnabotulinumtoxinA
Botulinum neurotoxinA
Preventive treatment
Guidelines
id ES_b3e4d32e84ca3c2d07e8aafe14a71add
oai_identifier_str oai:incliva.fundanetsuite.com:p2283
network_acronym_str ES
network_name_str España
repository_id_str
spelling Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice.Gago-Veiga ABSantos-Lasaosa SCuadrado MLGuerrero ÁLIrimia PLáinez JMLeira RPascual JSanchez Del Río MViguera JPozo-Rosich PConsensusChronic migraineOnabotulinumtoxinABotulinum neurotoxinAPreventive treatmentGuidelinesOnabotulinumtoxinA has been demonstrated to be effective as a preventive treatment in patients with chronic migraine (CM). Five years after the approval of onabotulinumtoxinA in Spain, the Headache Study Group of the Spanish Society of Neurology considered it worthwhile to gather a group of experts in treating patients with CM in order to draw up, based on current evidence and our own experience, a series of guidelines aimed at facilitating the use of the drug in daily clinical practice. For this purpose, we posed 12 questions that we ask ourselves as doctors, and which we are also asked by our patients. Each author responded to one question, and the document was then reviewed by everyone. We hope that this review will constitute a practical tool to help neurologists treating patients with CM. (C) 2017 Sociedad Espanola de Neurologia. Published by Elsevier Espana, S.L.U.ELSEVIER ESPANA SLU2019info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/2283NEUROLOGIAISSN: 02134853ISSNe: 15781968reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAEspañolinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p22832026-06-07T16:35:31Z
dc.title.none.fl_str_mv Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice.
title Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice.
spellingShingle Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice.
Gago-Veiga AB
Consensus
Chronic migraine
OnabotulinumtoxinA
Botulinum neurotoxinA
Preventive treatment
Guidelines
title_short Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice.
title_full Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice.
title_fullStr Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice.
title_full_unstemmed Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice.
title_sort Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice.
dc.creator.none.fl_str_mv Gago-Veiga AB
Santos-Lasaosa S
Cuadrado ML
Guerrero ÁL
Irimia P
Láinez JM
Leira R
Pascual J
Sanchez Del Río M
Viguera J
Pozo-Rosich P
author Gago-Veiga AB
author_facet Gago-Veiga AB
Santos-Lasaosa S
Cuadrado ML
Guerrero ÁL
Irimia P
Láinez JM
Leira R
Pascual J
Sanchez Del Río M
Viguera J
Pozo-Rosich P
author_role author
author2 Santos-Lasaosa S
Cuadrado ML
Guerrero ÁL
Irimia P
Láinez JM
Leira R
Pascual J
Sanchez Del Río M
Viguera J
Pozo-Rosich P
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Consensus
Chronic migraine
OnabotulinumtoxinA
Botulinum neurotoxinA
Preventive treatment
Guidelines
topic Consensus
Chronic migraine
OnabotulinumtoxinA
Botulinum neurotoxinA
Preventive treatment
Guidelines
description OnabotulinumtoxinA has been demonstrated to be effective as a preventive treatment in patients with chronic migraine (CM). Five years after the approval of onabotulinumtoxinA in Spain, the Headache Study Group of the Spanish Society of Neurology considered it worthwhile to gather a group of experts in treating patients with CM in order to draw up, based on current evidence and our own experience, a series of guidelines aimed at facilitating the use of the drug in daily clinical practice. For this purpose, we posed 12 questions that we ask ourselves as doctors, and which we are also asked by our patients. Each author responded to one question, and the document was then reviewed by everyone. We hope that this review will constitute a practical tool to help neurologists treating patients with CM. (C) 2017 Sociedad Espanola de Neurologia. Published by Elsevier Espana, S.L.U.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/2283
url https://incliva.portalinvestigacion.com/publicaciones/2283
dc.language.none.fl_str_mv Español
language_invalid_str_mv Español
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER ESPANA SLU
publisher.none.fl_str_mv ELSEVIER ESPANA SLU
dc.source.none.fl_str_mv NEUROLOGIA
ISSN: 02134853
ISSNe: 15781968
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417215561826304
score 15.811543

Similares en LA Referencia